Replies to post #114620 on Avid Bioservices Inc (CDMO)

[InternetForumUser]

Completely agree with your sentiments.

Reminds me when I was in Boy scout's and the long hikes we went on. On the longer days when we asked "Are we there yet?" the response was always "It's around the next bend." In the end we always got to our objective even though some days were longer than others.

In the case of PPHM, I really don't know if it is around the "next bend" or if there is just a void or a cliff. The company has existed since 1981 which seems like enough time to be more than a penny stock. I want to believe in Bavi; however, the lack of any "significant" information seems bewildering.

It would be great if Insiders started buying shares on the open market and display that they are optimistic about their future.

[biopharm]

..we waited for over a year for the FDA to approve a Cotara phase 3 trail that mgmt agreed upon and insisted upon but yet after another three months there is still no partner. Where are the partners they were talking with when they were waiting for the FDA decision?

----------------------------------------------------------------
we bring on Garnick... and yes, waited for a year... but that led Peregrine and Garnick to a successful result as seen below:

"The FDA has agreed with the company's proposed randomized trial design comparing two dose levels of Cotara in up to 300 patients. The trial design allows for multiple interim data analyses with the potential to stop patient accrual early based on predicted success or futility. Cotara has been granted orphan drug status and Fast Track designation..."

FDA agreed with the company... 300 patients... allowed to stop trial after early success (20..30..40 patients?)

I call that a major victory for Peregrine... "We appreciate the input that the FDA has provided to us during the course of our discussions in order to arrive at this mutually agreed upon design, that, if successful, should be sufficient to support a full marketing submission," said Robert Garnick, Ph.D., Peregrine's head of regulatory affairs. "Our next steps include the engagement of other regulatory agencies, where we plan to run the trial as part of a global registration study.""

thank you Mr. Garnick!

All in my opinion... as I don't ever remember a more important 30 day span in Peregrine history than the next 30 days.

GLTA!